App-Quantinova.ai

Poor Clinical Outcome in Pediatric Immunotherapy Is Mediated By a Pre-Existing Overactive IL-18-IFNy Immune Phenotype

Katelyn Burleigh - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Interferon Gamma

Early Administration of Partially HLA Matched Third Party Virus-Specific T-Cells in Conjunction with Antiviral Treatment for Initial Viral Infection after Allogeneic Stem Cell Transplant Is Safe and Leads to High Rates of Viral Control

Wei Jiang - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Filgrastim

Primary Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL)

Sattva S. Neelapu - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

B cell lymphomas

Axicabtagene ciloleucel

A First-in-Human Study of YTB323, a Novel, Autologous CD19-Directed CAR-T Cell Therapy Manufactured Using the Novel T-Charge TM platform, for the Treatment of Patients (Pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL)

Ian W. Flinn - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

N/A

MAIT and Vδ2 Unconventional T Cells Predict Favorable Outcome after Allogeneic HCT and Are Supported By a Diverse Intestinal Microbiome

Hana Andrlova - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Graft-versus-host disease

Ribo-100

Pharmacological Reduction of Mitochondrial Iron in AML Triggers a BAX/BAK Dependent Non-Canonical Cell Death Synergistic with Venetoclax

Sylvain Garciaz - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Ferrostatin-1

Diagnostic Utility of Multimodal Genomic Profiling for Molecular Classification and MRD Assessment in Adult B-Cell Acute Lymphoblastic Leukemia

Georgina L Ryland - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

B-cell acute lymphoblastic leukemia

N/A

Blinatumomab Is Cost-Effective Compared to Standard Chemotherapy for Children with High Risk Relapses of Acute Lymphoblastic Leukemia: A Cost-Effectiveness Analysis Using Population-Based Healthcare Data

Petros Pechlivanoglou - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Blinatumomab

Rates and Predictors of Visits to Primary Care Physicians during and after Treatment of Childhood Acute Lymphoblastic Leukemia: A Population-Based Cohort Study

Vicky R. Breakey - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

High-Dose Methotrexate Is Not Associated with Reduction in CNS Relapse in Patients with Aggressive B-Cell Lymphoma: An International Retrospective Study of 2300 High-Risk Patients

Katharine Louise Lewis - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

Methotrexate

Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Grzegorz S. Nowakowski - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

Lenalidomide

PDGF-BB and Its Role in Megakaryopoiesis and Thrombocythemia

Mo Yang - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Becaplermin

A Quantitative Systems Pharmacology (QSP) Model to Compare the Non-Clinical Biodistribution and Efficacy between Recombinant Factor IX (rIX) Therapies

Sabine Pestel - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Alprolix Intravenous

A Snapshot of Venous Thromboembolism (VTE): Retrospective Audit of Events at a Metropolitan Tertiary Referral Hospital

Julianne Chong - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

N/A

Quantification and Characterisation of Nano-Sized Particles in Cryoprecipitate Units

Ji Hui Hwang - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Fibrinogen (IV)

Tanshinone Iia Inhibits Megakaryopoiesis in Immune Vasculitis

Hui Chen - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

tanshinone IIA

Global Phase 3, Randomized, Placebo-Controlled Trial with Open-Label Extension Evaluating the Oral CXCR4 Antagonist Mavorixafor in Patients with WHIM Syndrome (4WHIM): Trial Design and Enrollment

David C. Dale - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Neutropenia

AMD-070

HMGN1 expression Predisposes Down Syndrome Patients to Develop P2RY8-CRLF2 acute Lymphoblastic Leukemia

Elyse C Page - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

Doxycycline

Effect of Thrombospondin-1 on Apoptosis of Human Megakaryocytic Leukemia Cells

Huimin Kong - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

thrombospondin-1

Expert Curation of Somatic FLT3 Variants By the Clingen Somatic Hematologic Cancer Taskforce (ClinGen HCT)

Xiangqiang Shao - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hematological malignancies

gilteritinib

Filters

13968 Abstracts